Ειδήσεις: PHASE 3 | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 13:32 investing.com

Karyopharm stock gains 10% on mixed Phase 3 trial data

Karyopharm Phase 3 trial stock gains mixed results oncology investor sentiment

24/03 13:27 yahoo.com

Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results

Vertex Pharmaceuticals Truist Securities price target Phase 3 trial biotech drug approval

23/03 15:10 statnews.com

STAT+: Pfizer’s Lyme vaccine results set up tricky regulatory path

Pfizer Lyme disease vaccine Phase 3 regulatory efficacy

23/03 13:00 statnews.com

STAT+: Insmed drug benefits patients with rare, bacterial lung disease, study shows

Insmed Arikayce MAC mycobacterium avium complex lung infection accelerated approval

16/03 09:02 defenseworld.net

Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference

Cytokinetics Myqorzo ACACIA‑HCM Phase 3 hypertrophic cardiomyopathy U.S. approval

15/03 09:11 defenseworld.net

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.3% – Should You Sell?

Capricor Therapeutics CAPR stock price Deramiocel FDA review PDUFA

15/03 09:11 defenseworld.net

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.3% – Should You Sell?

Capricor Therapeutics CAPR stock price Deramiocel FDA review PDUFA

Loading...